Literature DB >> 28729915

The Concomitant Association of Thyroid Disorders and Myasthenia Gravis.

Yu-Pei Lin1, Usman Iqbal2,3, Phung-Anh Nguyen3,4, Md Mohaimenul Islam4, Suleman Atique4, Wen-Shan Jian3,5,6, Yu-Chuan Jack Li3,4,7, Chen-Ling Huang1, Chung-Huei Hsu1,8.   

Abstract

BACKGROUND: Some of the thyroid disorders (TD) and Myasthenia gravis (MG) are autoimmune related disease. The purpose of the study to evaluate the relationship of MG with all morphological and functional thyroid disorders.
METHODS: We constructed a population-based cohort study during the period from January 2000-December 2002 by using reimbursement data from the Bureau National Health Insurance (NHI) system in Taiwan. Patients with TD and MG were identified by referring to the ICD-9-CM codes. (ICD-10-CM as reference) .The association of TD with MG occurred only in the same person within the study period. The Q value was used to measure the strength of disease-disease associations.
RESULTS: We obtained 520628 TD and 7965 MG records for analysis. Diffuse toxic goiter had highest association rate, followed by nontoxic nodular goiter, simple goiter, chronic lymphocytic thyroiditis, thyroid cancer, and toxic nodular goiter. Female and older patients had a higher rate than their male and younger counterparts, respectively. Functional abnormalities revealed higher incidence of thyrotoxicosis and hypothyroidism in both sexes. We also found the strongest association in men with chronic thyroiditis, diffuse toxic goiter, thyrotoxicosis, acquired hypothyroidism, thyroid cancer, and simple goiter. While an intermediate association was observed in female with diffuse toxic goiter, in a male with toxic and nontoxic nodular/multinodular goiters, in female with thyrotoxicosis, thyroid cancer and acquired hypothyroidism.
CONCLUSION: This population based cohort study showed potential association of all types of TD with MG, and observed a higher association rate in female autoimmune TD whereas males showed a higher strength of association.

Entities:  

Keywords:  Autoimmune thyroid disease; Graves’ disease; chronic lymphocytic thyroiditis; hypothyroidism; myasthenia gravis

Year:  2017        PMID: 28729915      PMCID: PMC5443889          DOI: 10.1515/tnsci-2017-0006

Source DB:  PubMed          Journal:  Transl Neurosci        ISSN: 2081-6936            Impact factor:   1.757


Introduction

Myasthenia gravis (MG) is a rare antibody-mediated autoimmune disease of the neuromuscular junctions which affects the neuromuscular junction, blocking synaptic neurotransmissions, and clinically symptomatic muscle weakness [1]. According to McGoogan et al. [2] MG is immunologically heterogeneous, with antibodies against the nicotinic acetylcholine receptor (AChR-Ab) in most patients (85%), and antibodies against muscle-specific receptor tyrosine kinase or lipoprotein-related protein 4 in a variable proportion of AChR-Ab-negative patients. A systemic review mentioned that incidence and prevalence rates of MG were estimated to be 5.4 per million person years and 77.7 per million persons, respectively [3]. Although there were remarkable variations among different studies, and the incidence varying from 1.7 to 21.3 per million person years, and the prevalence varying from 15 to 179 per million persons [3-6]. Autoimmune thyroid diseases (ATDs) are a heterogeneous group of disorders; the three major phenotypes such as patients with hyperthyroidism due to Graves’ disease (GD), patients with hypothyroidism due to Hashimoto’s thyroiditis (HT); and euthyroid patients with positive anti-thyroid autoantibodies. In 1908, Rennie first time reported the association of MG with Graves’ disease, an autoimmune thyroid disease (AITD) that are responsible for ocular myopathy and exophthalmos [7]. On the other hand, McEachern study suggested that there is no considerable evidence for the relationship between two diseases [8]. To find out the association between thyroid disease with MG; Sahay et al. found eight patients with MG of which 5 were of hypothyroidism and 3 of hyperthyroidism patients [9]. However, a study confirmed the coexistence of autoimmune diseases with MG and it was noticeable that AITD seemed to be more frequent compared with other autoimmune conditions. They mentioned AITD occurred more often in female and AChRAb serology-positive MG patients [10]. In the same vein Bollaert et al. [11] noted that the frequency of coexistence of autoimmune disease in patients with GD and Hashimot’s disease was reported to be 9.67% and 14.3%, respectively. Recently, literature has emerged that offers contradictory findings about the association of thyroid diseases with myasthenia gravis. But this paper attempt to show the association of myasthenia gravis with thyroid disorders through a large population cohort study. Moreover, this study also evaluated the cooccurrence rate of these two diseases and the strength of association.

Methods

In this study, we used data from the Taiwan’s National Health Insurance (NHI) database, comprising 782 million out-patient claims records including 10.8 million males and 10.6 million females from January 2000 to December 2002. We identified all patients with MG and thyroid disorders by referring to the International Classification of Disease, Clinical Modification, Ninth Revision [ICD-10-CM] codes (MG: code 358 I G70.01 ). We only consider MG patients associated with thyroid disorders only if patients occurred within the 3-year study period. Moreover, all of the records were stratified by sex and ages at a 20-year interval. Further, we divided thyroid disorders into 1. Morphological diseases: simple goiter (code 240, 240.0 I E04.9; E04.0) and non-toxic nodular/multinodular goiter (code 241, 241.0, 241.1, 241.9 I E04.1 I E04.2) 2. Coexisting functional and morphological diseases: diffuse toxic goiter (code 242.0, 242.00, 242.01 I E05.00 E05.01) and toxic nodular/multinodular goiter (code 242.1, 242.10, 242.11, 242.2, 242.20, 242.21, 242.3, 242.30, 242.31 /E05.10 E05.11 E05.20 E05.21) 3. Chronic lymphocytic thyroiditis (code 245.2 /E06.3) (4) thyroid cancer (code 193 I C73). Also, thyroid dysfunctions were collected separately according to code for further analysis: thyrotoxicosis (code 242.9, 242.90, 242.91 I E05.90 E05.91) and acquired hypothyroidism (code 244, 244.0, 244.1, 244.2, 244.3, 244.8, and 244.9 I E03.2 E03.8 E03.9 E89.0). In our study, each sub-set of thyroid disease used separately to quantify the strength of disease-disease association (co-occurrence). To measure the association between two diseases, we also calculate Q value. In this analysis we categorized Q value into three different groups such as strong (Q>10), Intermediate (Q=5-10) and weak (Q=1-4.99). A Q value has been used to measure strength of the associations between diseases

Results

We collected 7965 MG (4803 female and 3162 males) and 520628 cases of thyroid disorders (421512 female and 99116 male; female to male ratio= 4.3:1.0) for final analysis. Table 1 shows the asociation rate of MG and subset of thyroid disorders. It is apparent from Table 1 that toxic diffuse goiter had highest rate of 4.37%(348/7965female 4.96%, male 3.48%), that is followed by non-toxic nodular goiter 1.46% (116/7965; female 1.98%, male 0.66%), simple goiter1.19% (95/7965;female 1.46%, male 0.79%), chronic lymphocytic thyroiditis 0.60% (48/7965; female 0.67%, male 0.51%), thyroid cancer 0.34% (27/7965; female 0.42%, male 0.22%) and toxic nodular goiter 0.25% (20/7965; female 0.33%, male 0.13%). It is observed that every subset female patient’s rate had higher compared with male patients. From the data in table 1, it can also seen that in the case of functional disorders-thyrotoxicosis had 7.51% (598/7965;female 8.91%, male 5.38%) and hypothyroidism had 2.79% (222/7965; female 3.52%, male 1.68%) association rate. Interestingly, there were also differences in the ratio of male and female patients. The most striking result to emerge from the data is that 60-79 year-old patients observed higher association rate of 2.4% (168/7003) and then 20-39,40-59 and younger patients saw 0.75% (1627/215786), 0.3% (571/189793), and 0.26% (105/40669) respectively. A Q value of greater than 1 indicated a significant association between two diseases. Table 2 shows the strength of association betweem two diseases. It is noted that in male patients chronic lymphocytic thyroiditis Q value (30) had highest, and other conditions of this group are diffuse toxic goiter (Q=23.4), thyrotoxicosis (Q= 13.3), acquired hypothyroidism (Q=12.7), thyroid cancer (Q=12.4), and simple goiter (Q= 12.2). On the other hand, Toxic nodular/multinodular goiter and non-toxic nodular/multinodular goiter in male patients Q value had 7.6 and 6.2,; as well as diffuse toxic goiter, thyrotoxicosis, thyroid cancer and acquired hypothyroidism of the female patients observed Q value 8.5, 6.1,5.9 and 5.7 respectively. Simillarly only female patients with toxic nodular/multinodular goiter (Q=4.9), chronic lymphocytic thyroiditis (Q=4.6), simple goiter (Q=4.5), and non-toxic nodular/ multinodular goiter (Q=2.9) included in weak association group.
Table 1

Association rates of 520628 cases of thyroid disorders (421512 female and 99116 male cases) and 7965 cases of myasthenia gravis (4803 female and 3162 male cases); the strength of association values (Q values) are listed.

Thyroid disorderGenderNo.Co-occurrence No.Association Rate (%)Q value
Simple goiterFemale34488701.464.51
Male7649250.7911.2
Non-toxic nodular/multinodular goiterFemale72695951.982.90
Male11644210.666.19
Diffuse toxic goiterFemale618992384.968.54
Male161651103.4823.4
Toxicnodular/multinodular goiterFemale7224160.334.92
Male179840.137.63
Chronic lymphocytic thyroiditisFemale15401320.674.62
Male1830160.5130.0
Thyroid cancerFemale7483200.425.94
Male194070.2212.4
ThyrotoxicosisFemale15619 74288.916.09
Male438091705.3813.3
Acquired HypothyroidismFemale661251693.525.68
Male14281531.6812.7
Table 2

Strength of the association values of thyroid disorders and MG.

Q valueThyroid disorders (M=male, F=female) (Q value)
>10(strong)chronic lymphocytic thyroiditis of M (30.0) diffuse toxic goiter of M (23.4)thyrotoxicosis of M (13.3)acquired hypothyroidism of M (12.7) thyroid cancer of M (12.4)simple goiter of M (11.2)
5-10(intermediate)diffuse toxic goiter of F (8.5)toxic nodular/multinodular goiter of M (7.6)non-toxic nodular/multinodular goiter of M (6.2) thyrotoxicosis of F (6.1)thyroid cancer of F (5.9)acquired hypothyroidism of F (5.7)
1-4.9(weak)toxic nodular/multinodular goiter of F (4.9) chronic lymphocytic thyroiditis of F (4.6)simple goiter of F (4.5)non-toxic nodular/multinodular goiter of F (2.9)
Association rates of 520628 cases of thyroid disorders (421512 female and 99116 male cases) and 7965 cases of myasthenia gravis (4803 female and 3162 male cases); the strength of association values (Q values) are listed. Strength of the association values of thyroid disorders and MG.

Discussion

The present study was designed to determine Myasthenia gravis (MG) correlate with the different thyroid disorder. In this large population-based study, we found myasthenia moderately associated with thyroid disorders. It is interesting to note that all subcategories of thyroids had an association with myasthenia gravis, and its rate had 0.25-4.37 percent. Thyroid disease in patients must be categorized into functional disorder, morphological disorder and or combined disorder. For example, Graves’disease is diffuse toxic goiter. Toxic means hyper function and Diffuse means morphological enlargement. Therefore, we tried to classify accordingly shown in the study. For example, simple goiter is enlargement of thyroid but within normal thyroid function range. While Fang et al. [12] recently published an article that showed higher rate of association than our study result. In addition, previous studies also support our result and mentioned the significance relationship between thyroid disorders and myasthenia gravis [9, 13-15].The association of MG and AITD has been identified in autoimmune polyendocrine syndrome type Il (APS-II), which comprises Addison’s disease, AITD (GD and hypothyroidism caused by chronic lymphocytic thyroiditis), MG, type 1 diabetes, and others [16]. In 2009, Martignago et al. [17] mentioned this major study; The AChR-Ab seropositive MG is associated with thymoma or thymic hyperplasia and thyroid disease. So, it is clear to understand that autoimmunity always plays a critical role in the association of MG and thyroid disorders. Our study reveals that Al-related thyroid disorders including diffuse toxic goiter, chronic lymphocytic thyroiditis had the higher number of female patients. This result is accord with previous studies indicating that diffuse toxic goiter is greater in female [18-20]. It is somewhat surprising that male patients with diffuse toxic goiter and chronic lymphocytic thyroiditis had a strong association with myasthenia gravis. On the contrary, the female patient with these two thyroid diseases showed an intermediate and weak association. Although we observed that female had a higher number in case of all thyroid diseases, but male patients with thyroid conditions showed strong association with myasthenia gravis. In fact, the prevalence rate of thyroid disease is most common in females. However, if male suffer with thyroid disease, we assume that it is usually more serious and not easy to treat. Mostly thyroid disease are more common in females than male including morphological and functional thyroid disorders. If a man has thyroid disease such as Graves’ disease, the symptoms and signs are more serious in male than female based on clinical experience .Also the prognosis is worse in males compared to females [21,22]. In our study, we tried to figure out the reason for higher strength of association in male when compare with female. Q value of chronic lymphocytic thyroiditis had 30 which is much higher than any other thyroid diseases. The result of this study also showed that male patients with diffuse toxic goiter, thyrotoxicosis, acquired hypothyroidism, thyroid cancer, and simple goiter had a strong association with myasthenia gravis. These results seem to be consistency with other results which found this thyroid disease is related to myasthenia gravis [23-25]. It is, therefore, likely that such connections exist between thyroid disorders and myasthenia gravis. Mao ZF et al. [10] showed that autoimmune thyroid disease is more coexisted with myasthenia gravis. Similarly, Tamer et al. [26] has confirmed this view and mentioned, autoimmune thyroid disease (16%) are associated with myasthenia gravis. Simple goiter, alternatively termed diffuse non-toxic goiter, mostly affects female and is caused by the inability of the thyroid to produce a sufficient amount of hormones for body requirement, resulting in the enlargement of the thyroid (goiter) and eventually euthyroid. The considered etiologies were mainly due to inadequate iodine intake or people living in an endemic iodine deficiency area (endemic goiter), the ingestion of goitrogenic food, drugs or chemicals, smoking, stress, and heredity. Non-toxic nodular/multinodular goiter is functionally euthyroid and benign in the nodules histopathology. They are the most common morphological thyroid disorders that consist of the pure cyst, colloid nodules, adenoma, granulomatous disease or focal thyroiditis.

Conclusions

This study has identified, Myasthenia is positively associated with all thyroid disorders. We observed a higher association rate of autoimmune thyroid disease in females but in older males had a higher strength of association. The result of this study also indicates that the co-existence of autoimmunity play significant roles in the pathogenesis. Further studies need to be carried out to validate the association between two diseases.
  23 in total

1.  Clinical features of patients with myasthenia gravis associated with autoimmune diseases.

Authors:  M Kanazawa; T Shimohata; K Tanaka; M Nishizawa
Journal:  Eur J Neurol       Date:  2007-10-17       Impact factor: 6.089

2.  Autoimmune thyroid disease with myasthenia gravis in a 28-year-old male: a case report.

Authors:  Imran Masood; Mir Yasir; Aiffa Aiman; R P Kudyar
Journal:  Cases J       Date:  2009-09-14

Review 3.  The incidence of myasthenia gravis: a systematic literature review.

Authors:  Anita McGrogan; Samantha Sneddon; Corinne S de Vries
Journal:  Neuroepidemiology       Date:  2010-02-02       Impact factor: 3.282

4.  Coexistence of autoimmune diseases and autoantibodies in patients with myasthenia gravis.

Authors:  Sibel Tamer; Hafize Nalan Gokce Gunes; Elif Gokcal; Tahir Kurtulus Yoldas
Journal:  Neurol India       Date:  2016 Jan-Feb       Impact factor: 2.117

5.  PRENATAL INFECTION, MATERNAL IMMUNE ACTIVATION, AND RISK FOR SCHIZOPHRENIA.

Authors:  Sarah E Canetta; Alan S Brown
Journal:  Transl Neurosci       Date:  2012-12-01       Impact factor: 1.757

6.  Evidence of underdiagnosis of myasthenia gravis in older people.

Authors:  A Vincent; L Clover; C Buckley; J Grimley Evans; P M Rothwell
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

Review 7.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

8.  Concurrent Graves disease thyrotoxicosis and myasthenia gravis: the treatment of the former may dangerously reveal the latter.

Authors:  K Lakhal; Y Blel; M Fysekidis; K Mohammedi; L Bouadma
Journal:  Anaesthesia       Date:  2008-06-02       Impact factor: 6.955

9.  RELATION BETWEEN MYASTHENIA GRAVIS AND THYROID DISEASE.

Authors:  B M SAHAY; L M BLENDIS; R GREENE
Journal:  Br Med J       Date:  1965-03-20

10.  Higher risk of myasthenia gravis in patients with thyroid and allergic diseases: a national population-based study.

Authors:  Jiann-Horng Yeh; Huang-Tsung Kuo; Hsuan-Ju Chen; Yen-Kung Chen; Hou-Chang Chiu; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

View more
  3 in total

Review 1.  Thymus pathology in myasthenia gravis with anti-acetylcholine receptor antibodies and concomitant Hashimoto's thyroiditis. A four-case series and literature review.

Authors:  Lidia Ionescu; Claudia Florida Costea; Radu Dănilă; Camelia Margareta Bogdănici; Dragoş Viorel Scripcariu; Roxana Maria Livădariu; Gabriela Florenţa Dumitrescu; Cristina Maria Gavrilescu; Raluca Alina Dragomir; Anca Sava; Andrei Ionuţ Cucu; Daniela Maria Tănase; Mihaela Dana Turliuc; Delia Gabriela Ciobanu Apostol
Journal:  Rom J Morphol Embryol       Date:  2021 Jan-Mar       Impact factor: 1.033

2.  Analysis of clinical features of myasthenia gravis complicated with hyperthyroidism.

Authors:  Yaxuan Wang; Guoyan Qi; Ying Yang
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 1.088

3.  Myasthenia Gravis and Associated Diseases.

Authors:  Nikolina Tanovska; Gabriela Novotni; Slobodanka Sazdova-Burneska; Igor Kuzmanovski; Bojan Boshkovski; Goran Kondov; Marija Jovanovski-Srceva; Anita Kokareva; Rozalinda Isjanovska
Journal:  Open Access Maced J Med Sci       Date:  2018-03-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.